Cognition | Jotup

Alpha Cognition to Present at the Life Science Investor Forum March 7th

Retrieved on:

Friday, March 1, 2024

Food and Drug Administration, Cognition, Food, Patent, Patient, NDA, Pharmaceutical industry

This will be a live, interactive online event where investors are invited to ask the company questions in real-time.

Key Points:

This will be a live, interactive online event where investors are invited to ask the company questions in real-time.
It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates.
ALPHA-1062 has a Prescription Drug User Fee Act (“PDUFA”) date (drug approval date) in the US for July 27, 2024.
Alpha Cognition filed new composition of matter patent for world-wide review in February.

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava

Retrieved on:

Friday, March 1, 2024

Scientific misconduct, Court, Alzheimer's disease, FDA, News, Advertising, Data management, Neurobiology of Aging, Initiative, Safety, Biomarker, Patient, Cognition, Journal, LLP, Science, Cassava Sciences, City University, Pharmaceutical industry

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Key Points:

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
The firm has recovered hundreds of millions of dollars for investors since its founding in 1995.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Cassava’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ).

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Boeing, Brooge, Cassava, and Amylyx and Encourages Investors to Contact the Firm

Retrieved on:

Friday, March 1, 2024

Its Commercial Airplanes Segment is a leading producer of commercial aircraft and offers a family of commercial jetliners including its 737 MAX.

Key Points:

Its Commercial Airplanes Segment is a leading producer of commercial aircraft and offers a family of commercial jetliners including its 737 MAX.
Throughout the Class Period, Defendants continued to assure investors that Boeing was laser-focused on safety and quality.
These false and misleading statements caused Boeing stock to trade at artificially inflated prices during the Class Period.
Also, according to the filed complaint, it took a near disaster to expose this heightened safety risk.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines – SAVA

Retrieved on:

Wednesday, February 28, 2024

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA).

Key Points:

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA).
To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext.
Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Retrieved on:

Tuesday, February 27, 2024

Enrollment continues in the global Phase 2/3 COMPASS study and is expected to be completed in 2024.

Key Points:

Enrollment continues in the global Phase 2/3 COMPASS study and is expected to be completed in 2024.
Sanofi intends to present the detailed efficacy and safety results of the ALS Phase 2 HIMALAYA study at a future scientific forum.
There was no collaboration revenue for the quarter ended December 31, 2023, compared to $10.3 million for the quarter ended December 31, 2022.
Further, for the quarter ended December 31, 2023, there was also a decrease in other unallocated research and development expenses as a result of reduced facility costs.

Empowering Women in Dentistry: Austin Oral Surgery’s 2024 Lucy Hobbs Project Seeks to Overcome Burnout, Cultivate Belonging and End Human Trafficking

Retrieved on:

Tuesday, February 27, 2024

In fact, Deloitte’s Human Capital Trends report ranked belonging as the top human capital issue that organizations face today.

Key Points:

In fact, Deloitte’s Human Capital Trends report ranked belonging as the top human capital issue that organizations face today.
End Human Trafficking, Ignite Hope will be presented by Liz Griffin, the executive director of Unbound Now Austin, a 501c3 nonprofit that is dedicated to extinguishing human trafficking and igniting hope.
Lucy Hobbs Project attendees will have the opportunity to earn up to five units of continuing education credit.
In addition, the event will include a brunch buffet, networking, shopping and opportunities to raise funds and awareness for Unbound Now Austin.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Boeing, Brooge, Cassava, and Amylyx and Encourages Investors to Contact the Firm

Retrieved on:

Monday, February 26, 2024

Its Commercial Airplanes Segment is a leading producer of commercial aircraft and offers a family of commercial jetliners including its 737 MAX.

Key Points:

Its Commercial Airplanes Segment is a leading producer of commercial aircraft and offers a family of commercial jetliners including its 737 MAX.
Throughout the Class Period, Defendants continued to assure investors that Boeing was laser-focused on safety and quality.
These false and misleading statements caused Boeing stock to trade at artificially inflated prices during the Class Period.
Also, according to the filed complaint, it took a near disaster to expose this heightened safety risk.

Cognition Therapeutics to Present at the TD Cowen Health Care Conference

Retrieved on:

Monday, February 26, 2024

Cognition, Therapy, Conference

PURCHASE, N.Y., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates designed to treat neurodegenerative disorders, announced today that the Company’s president and CEO, Lisa Ricciardi will present at the TD Cowen 44th Annual Health Care Conference taking place March 4-6, 2024.

Key Points:

PURCHASE, N.Y., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates designed to treat neurodegenerative disorders, announced today that the Company’s president and CEO, Lisa Ricciardi will present at the TD Cowen 44th Annual Health Care Conference taking place March 4-6, 2024.
During her presentation, Ms. Ricciardi will highlight Cognition’s pipeline progress, including upcoming clinical milestones and recent corporate achievements.
Details of Cognition’s presentation are as follows:
A live webcast of the presentation will be available on the “ events and presentations ” section of Cognition’s investor relations site, and an archived replay will be available for playback 90 days following the event.

Red light therapy for neuro/cognitive benefits

Retrieved on:

Friday, February 23, 2024

There is a simple and practical way – red light therapy to improve your brain function.

Key Points:

There is a simple and practical way – red light therapy to improve your brain function.
Red light therapy (RLT), also known as low-level laser therapy (LLLT) or photobiomodulation (PBM), involves exposure to specific wavelengths of visible red and near-infrared light (660-850 nm) to stimulate biological processes in the body.
Red light therapy increases mitochondria function to promote balance between free radicals and antioxidants in the body.
Studies have highlighted red light therapy has a potential neuroprotective and disease-modifying role in treating Alzheimer's and Parkinson's patients.

CASSAVA SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Cassava To Contact Him Directly To Discuss Their Options

Retrieved on:

Friday, February 23, 2024

NEW YORK, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA) and reminds investors of the April 2, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Key Points:

If you suffered losses exceeding $100,000 investing in Cassava stock or options between August 18, 2022 and October 12, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext.
Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Cassava’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.